Sangamo BioSciences Inc. has developed a technology that disrupts the CCR5 gene – the gateway for the human immunodeficiency virus (HIV) to enter immune system T-cells. They plan to begin a human clinical trials of its therapy in HIV patients in 2006.
Sangamo’s therapy would draw tens of millions of T-cells from a patient, disrupt the CCR5 gene in them, amplify the cells so there are about 1 billion of them and reinfuse them into the patient. Doing so would provide a reservoir of healthy and uninfectable T-cells that would fight both opportunistic infections and HIV itself. Once altered, those cells’ CCR5 genes are permanently modified.
MSNBC, December 25, 2005
Technorati Tags: hiv, aids, genes, ccr5, genetics, health, dna
Did this study really happen yet? What were the results? I just recently got diagnosed with HIV, am not on meds yet and wondering it this could help me still? I’d love to have some killer T-cell running around my body before meds. Or is this considered a med? with side-effects?
would like to someone to chat withregarding anal squamous cancer?
[...] One part of BioGrid is GoPubMed, an enhanced search of PubMed – a public database of biomedical literature. GoPubMed is an ontology-based literature search that shows the relationship between key concepts. To test it out, I keyed in CCR5. In the left hand column, it shows the key roles CCR5 plays in biological processes, as a ceullar component, and its molecular function with even more specific categories under each of these subheadings; these categories are called “GO Terms.” It also pulls the 100 most relevant articles and tags it with the GO Terms. The GO Terms are also highlighted in the abstracts. [...]
[...] For more information on HIV/AIDS, see HIV Gene Therapy. If you’d like to read more HIV POZ blogs, see HIV/AIDS Web Logs. [...]